Přihlásit se Zaregistrujte se zdarma

Předpokládaný růst EPS Q/Q společnosti Acelrx Pharmaceuticals Inc

Jaká je hodnota metriky Předpokládaný růst EPS Q/Q společnosti Acelrx Pharmaceuticals Inc?

Hodnota metriky Předpokládaný růst EPS Q/Q společnosti Acelrx Pharmaceuticals Inc je -14.29%

Jaká je definice metriky Předpokládaný růst EPS Q/Q?



Očekávaný čtvrtletní růst EPS (Estimated quarterly EPS growth rate) meziročně je předpokládaným nárůstem EPS společnosti pro příští čtvrtletí ve srovnání s výsledkami z minulého čtvrtletí.

The prospective EPS growth rate is a predicted estimate of the earnings per share growth rate towards the current quarter and expressed as a percentage compared to the respective past quarter. The estimated earnings per share growth rate is an important factor for judging a company's value. Comparing EPS history with stock price history helps determine the most likely future direction of the stock price.

Earnings per share is the monetary value of earnings per outstanding share of common stock for a company. The EPS is usually calculated as profit without preferred dividends divided by weighted average of common stock shares over the past twelve months.

Předpokládaný růst EPS Q/Q společností v sektoru Health Care sektor na NASDAQ ve srovnání se společností Acelrx Pharmaceuticals Inc

Čemu se věnuje společnost Acelrx Pharmaceuticals Inc?

acelrx pharmaceuticals inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. the company’s product candidates, dsuvia™ (known as arx-04 outside of the united states) and zalviso®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. dsuvia is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. the phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. in clinical studies, dsuvia demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and v

Firmy s metrikou předpokládaný růst eps q/q podobnou společnosti Acelrx Pharmaceuticals Inc